Zacks Investment Research Lowers Astellas Pharma (OTCMKTS:ALPMY) to Hold

Astellas Pharma (OTCMKTS:ALPMY – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

According to Zacks, “Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan. “

A number of other analysts have also recently weighed in on ALPMY. Jefferies Financial Group cut shares of Astellas Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, February 23rd. Citigroup initiated coverage on shares of Astellas Pharma in a report on Tuesday, April 12th. They issued a “buy” rating on the stock.

ALPMY stock traded down $0.10 during mid-day trading on Monday, reaching $14.94. The company had a trading volume of 432,300 shares, compared to its average volume of 108,072. The firm has a 50 day moving average of $15.83 and a 200 day moving average of $16.36. The company has a market capitalization of $27.43 billion, a PE ratio of 24.90 and a beta of 0.57. Astellas Pharma has a 12 month low of $14.65 and a 12 month high of $18.46.

About Astellas Pharma (Get Rating)

Astellas Pharma Inc engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant.

Featured Articles